GLP1R and metabolic dysfunction-associated steatotic liver disease: Also, semaglutide was never compared with pioglitazone, which, along with GLP-1 Ras, is the preferred treatment for T2D with NAFLD, according to the recent American Diabetes Association (ADA) [19].